Does a palliative care consult decrease the cost of caring for hospitalized patients with dementia?
Palliat Support Care. 2013 Oct 21:1-6.
Araw M, Kozikowski A, Sison C, Mir T, Saad M, Corrado L, Pekmezaris R, Wolf-Klein G.
Source
North Shore-Long Island Jewish Health System, Great Neck, New York.Abstract
Objective: Advanced dementia (AD) is a terminal disease. Palliative care
is increasingly becoming of critical importance for patients afflicted
with AD. The primary objective of this study was to compare pharmacy
cost before and after a palliative care consultation (PCC) in patients with end-stage dementia.
A secondary objective was to investigate the cost of particular types
of medication before and after a PCC. Method: This was a retrospective
study of 60 hospitalized patients with end-stage dementia at a large academic tertiary care
hospital from January 1, 2010 to October 1, 2011, in order to
investigate pharmacy costs before and after a PCC. In addition to
demographics, we carried out a comparison of the average daily pharmacy
cost and comparison of the proportion of subjects taking each medication
type (cardiac, analgesics, antibiotics, antipsychotics and antiemetics)
before and after a PCC.
Results: There was a significant decrease in overall average daily pharmacy cost from before to after a PCC ($31.16 ± 24.71 vs. $20.83 ± 19.56; p < 0.003). There was also a significant difference in the proportion of subjects taking analgesics before and after PCC (55 vs. 73.3%; p < 0.009), with a significant average daily analgesic cost rise from pre- to post-PCC: $1.36 ± 5.07 (median = $0.05) versus. $2.35 ± 5.35 (median = $0.71), respectively, p < 0.011; average daily antiemetics cost showed a moderate increase from pre- to post-PCC: $0.08 ± 0.37 (median = $0) versus $0.23 ± 0.75 (median = $0), respectively, p < 0.047.
Significance of results: Our findings indicate that PCC is associated with overall decreased medication cost in hospitalized AD patients. Additionally, receiving a PCC was related to greater use of pain medications in hospitalized dementia patients. Our study corroborates the benefits of palliative care team intervention in managing elderly hospitalized dementia patients.
Results: There was a significant decrease in overall average daily pharmacy cost from before to after a PCC ($31.16 ± 24.71 vs. $20.83 ± 19.56; p < 0.003). There was also a significant difference in the proportion of subjects taking analgesics before and after PCC (55 vs. 73.3%; p < 0.009), with a significant average daily analgesic cost rise from pre- to post-PCC: $1.36 ± 5.07 (median = $0.05) versus. $2.35 ± 5.35 (median = $0.71), respectively, p < 0.011; average daily antiemetics cost showed a moderate increase from pre- to post-PCC: $0.08 ± 0.37 (median = $0) versus $0.23 ± 0.75 (median = $0), respectively, p < 0.047.
Significance of results: Our findings indicate that PCC is associated with overall decreased medication cost in hospitalized AD patients. Additionally, receiving a PCC was related to greater use of pain medications in hospitalized dementia patients. Our study corroborates the benefits of palliative care team intervention in managing elderly hospitalized dementia patients.
No comments:
Post a Comment